DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
A••••••••• L••
Drug Discovery & Developmentgroup grade Aoff every schedule since Mar 31, 2025sponsor not established · possible relationship
Nothing material in the last 200 days. Last change: 31 Mar 2025, Consensus mark 56¢ on cost, down from 101¢ a year ago, 101¢ last quarter.
Mark path, consensus per quarter end
101¢ · 102¢ · 102¢ · 101¢ · 56¢Q1 2024 to Q1 2025
Principal held
at least $22.5M
sum of BDC pieces, a lower bound
Fair value
$13.1M
56c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
1 equity pieces beside them
Next maturity
Jan 1, 2027
$22.5M inside 24 months
On the tape since
Dec 31, 2022
latest Mar 31, 2025
Events
2
dated, non-routine
Lender marks
each lender's own fair value over cost at Mar 31, 2025, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| H••••••• C••••••• I••• | $22.5M | 56¢ | -45 pts |
Every BDC piece · 2 positions across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | term loan first lien S••••• S••••••, M••••••• D••• J•••••• 2027, P•••• + 2.50%, F•••• rate 9.50%, Cap rate 10.7 | $22.5M | $13.1M 56c | S+250 bp |
| H••••••• C••••••• I••• | warrants equity W••••••, A••••••••• D••• 12/27/2022, Series C•••• A U•••• | Not disclosed | $0 0c |
Capital structure as the BDCs see it
latest quarter end Mar 31, 2025
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Mar 31, 2025 | at least $22.5M | 56c | S+250 bp | Jan 1, 2027 | 1 |
Equity pieces beside the debt: warrants ($0 fair value, 1 BDC)
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Mar 31, 2025 | 1 | $22.5M | $13.1M | 56c | 0 |
| Dec 31, 2024 | 1 | $48.0M | $49.9M | 101c | 0 |
| Sep 30, 2024 | 1 | $24.0M | $24.9M | 102c | 0 |
| Jun 30, 2024 | 1 | $24.0M | $24.8M | 102c | 0 |
All 10 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Mar 31, 2024 | 1 | $24.0M | $24.6M | 101c | 0 |
| Dec 31, 2023 | 1 | $48.0M | $49.0M | 102c | 0 |
| Sep 30, 2023 | 1 | $24.0M | $24.0M | 100c | 0 |
| Jun 30, 2023 | 1 | $24.0M | $23.7M | 99c | 0 |
| Mar 31, 2023 | 1 | $24.0M | $23.8M | 100c | 0 |
| Dec 31, 2022 | 1 | $24.0M | $23.7M | 100c | 0 |
What changed
- Facility left every BDC scheduleMar 31, 2025
- Marked down across lendersMar 31, 2025
- Marked down (one lender)Mar 31, 2025
Sponsor
Possible relationship, not established: V••••• G••••• I•••••••• L•, because a company of this name is on the sponsor's portfolio page (confidence 0.6). No deal announcement or filing names it as a party, so it is not shown as this borrower’s sponsor.
- V••••• G••••• I•••••••• L•
- the sponsor's own portfolio page lists a company of this nameestimatedvikingglobal.com"••• Locked"
Identity
- Group key
- AMPLIFYBIOderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it